Initiate at 0.6% of portfolio only (not 1.2%), tighten stop to $345 (not $343), cap maximum exposure at 2% of portfolio (not 4%), require multi-day closes above $378 with RSI sustained above 50 before any add-on triggers, and exit if conditions don't materialize within 2-3 weeks.

• Stock down 25% over trailing twelve months while S&P is up 19.3%
• ISRG is below all three major moving averages (10/50/200-day)
• MACD is negative, still below signal line, histogram printing red bars (values decelerated from -8 to -2 but still negative)
• RSI at 42.57 in a persistent downtrend can stay in the 40-50 band for weeks
• Stock printed $350.16 just days ago, down 4.51% in a single session
• Beta of 1.47 indicates ISRG is being treated as a growth name, not defensive despite razor-and-blade economics
• Trailing P/E of 41x gets crushed when discount rates rise
• Traders own plan requires high-volume close above $378 before adding — same discipline should apply to initial entry
• Aggressive entry at $360, stop at $343 = $17 risk per share; upside to $378 = 4.7% potential gain
• Probability of testing/breaking $343 estimated at 40-50%; probability of closing above $378 estimated at 30-40%
• If stop at $343 breaks, downside target is $320s (another 7-10% loss)
• Full aggressive exposure of 3.2-4% in a 1.47-beta name could cause 40-60 basis points of portfolio drawdown in macro shock
• Zero Reddit posts across WallStreetBets, stocks, and investing despite 25% drop suggests no retail FOMO bid
• Price action and sentiment articles are diverging — price action pays the bills

→ vs aggressive: Dismissing waiting for SMA reclaim isn't 'paralysis' — it's preservation of optionality with 100% capital available and zero exposure to a name down 25% TTM; the aggressive analyst's own plan requires confirmation above $378 to add, contradicting their case for entry at $360

→ vs aggressive: Claiming 'technicals without fundamentals are half a trade' ignores that the market is sending clear signals through multiple negative indicators; the trader themselves acknowledged ISRG is below all major MAs with elevated-beta macro and competitive risks

→ vs aggressive: MACD histogram decelerating from -8 to -2 isn't a buy signal — a car slowing from 80mph to 20mph is still moving forward; MACD remains negative, below signal line, with red bars still printing

→ vs aggressive: RSI at 42.57 in a persistent downtrend can stay at 40-50 for weeks; the aggressive analyst dismissed oversold bounce while simultaneously arguing for entry before the most basic momentum shift has occurred

→ vs aggressive: Institutional 'smart money positioning' argument ignores that $350.16 print with -4.51% single-day drop looks like institutional distribution to retail dip-buyers, not accumulation; zero retail chatter despite 25% drop means no FOMO catalyst

→ vs aggressive: Stagflation/defensive compounder argument is 'dangerous' — the market has voted with capital by selling ISRG 25% while healthcare defensives held better; beta of 1.47 means the market treats ISRG as growth, not defense, and 41x trailing P/E gets crushed in higher-for-longer

→ vs aggressive: Asymmetric risk/reward framing of $17 risk and 4.7% reward ignores probability-weighting; with 40-50% probability of hitting $343 stop (and potential $320s downside) versus 30-40% probability of reaching $378, the coin flip has a slight negative skew — not asymmetric in the firm's favor

→ vs aggressive: 'Starter position' framing of 1.2% ignores that full deployment reaches 3.2-4% of portfolio in a single downtrending name with 1.47 beta in hostile macro; even the 'conservative' version carries meaningful drawdown risk

Initiate 0.8% starter position at $360 entry, cap maximum combined exposure at 2.5%, require two consecutive closes above $378 (rather than one) before triggering the 1.2% add, keep the $343 stop level unchanged, add a 30-day time-based re-evaluation trigger if no confirmation signals materialize, and avoid initiating within 6-8 weeks of earnings due to 10-15% single-session volatility risk.

• Market is pricing in legitimate multiple compression concern at 41x trailing P/E in higher-for-longer rate environment; ~30x forward multiple is not unfair but requires macro cooperation not currently present.
• Probability-weighted R:R is roughly symmetric on near-term basis: ~35% probability of upside completion vs ~45% probability of stop-out over 30-60 day window; asymmetry only emerges over 6-12 month horizon.
• Conservative analyst's 0.6% sizing is 'token gesture' for a 'buy of the decade' thesis—too small to matter if right, too small to hurt if wrong.
• Cash position represents implicit directional bet against ISRG falling further, not a neutral stance; waiting for 50 SMA reclaim could mean buying at $400+ after missing basing action.
• Lack of retail FOMO is actually positive—it means no crowded long trade to unwind.
• Fundamental picture is compelling: 18.5% revenue growth, 26.5% EPS growth, 310 basis points of margin expansion, debt-free balance sheet with $8.6 billion in liquid investments.
• Technical picture is hostile: stock below all three major moving averages, negative momentum, 1.47 beta in risk-off macro environment (multiyear-high yields, oil above $100, 93% probability of no Fed cut in 2026).
• Earnings risk is an unrecognized tail risk: ISRG historically moves 10-15% in single session regardless of pre-earnings thesis.
• Maximum 4% concentration in single high-beta name in confirmed downtrend contributes 40-60 basis points of portfolio drawdown per 10-15% stock decline—too concentrated.
• Original plan structure (staged entry, conditional adds, clear invalidation) is sound; execution parameters need tightening to respect both fundamental conviction and technical uncertainty.

→ vs aggressive: Central thesis overshoots by treating market as 'wrong' about ISRG; market is rationally pricing multiple compression risk in current macro environment. Probability-weighted R:R analysis is too optimistic—treating a 35% upside vs 45% downside as 'asymmetric' is inaccurate on near-term trading horizon.

→ vs conservative: 0.6% sizing is too small for a position described as 'buy of the decade'—that's a placeholder, not a position. Framing cash as 'fortress' is actually a directional bearish bet with opportunity cost. Institutional sentiment analysis underweights the positive signal of no retail FOMO (no crowded trade to unwind).